Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387957 · ClinicalTrials.gov registry record · Phase 2
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
A Phase 2 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02387957: Clinical Trial Phase 2 study, sponsored by Ophthotech Corporation.
NCT02387957 is a Phase 2 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02387957, a Phase 2 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
Interventions
- DRUG bevacizumab
- DRUG ranibizumab
- DRUG aflibercept
- DRUG Fovista®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2016-04-26 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387957
The ClinicalTrials.gov registry entry for NCT02387957 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT02387957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387957 about?
NCT02387957 is a clinical study titled "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)". To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
What is the current status of trial NCT02387957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2016-04-26. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02387957?
The interventions under investigation include: bevacizumab (DRUG), ranibizumab (DRUG), aflibercept (DRUG), Fovista® (DRUG).
Who is sponsoring clinical trial NCT02387957?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.